Frailty, Innovation, and the Future of Myeloma Treatment With Joseph Mikhael, MD

To mark the conclusion of Multiple Myeloma Awareness Month, we’re diving into a conversation that sits at the intersection of innovation, aging, and equity in cancer care. We’re joined by Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer with the International Myeloma Foundation and professor in the Applied Cancer Research and Drug Discovery Division of the Translational Genomics Research Institute.

Mikhael has spent more than 25 years advancing the treatment of multiple myeloma, and in that time he’s witnessed a remarkable shift: older adults—once left behind by intensive therapies—are now benefiting from safer, more targeted, and more effective options. In this episode, he breaks down how improved survival, evolving frailty assessments, and the rise of options like chimeric antigen receptor T-cell therapies and bispecific antibodies are reshaping care for an aging population. He also highlights the growing emphasis on quality of life, caregiver support, and expanding clinical trial access.

Listen above or on one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify